Senators Ask CMS To Pause Biosimilar Payment Rule
This article was originally published in Scrip
Executive Summary
A group of 20 US senators on Oct. 8 asked the Centers for Medicare & Medicaid Services (CMS) to postpone its proposed rule, which seeks to lump biosimilars referenced on the same innovator into the same Medicare Part B reimbursement rate, until after the FDA has completed its regulations and the pipeline and the market for the products are "safe and stable."